Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S197000, C544S198000, C544S208000, C544S209000, C544S213000, C544S217000, C544S218000
Reexamination Certificate
active
06906067
ABSTRACT:
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I:Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.
REFERENCES:
patent: 3290305 (1966-12-01), Schmitz et al.
patent: 3590042 (1971-06-01), Cyba
patent: 3625979 (1971-12-01), Heimberger
patent: 3867383 (1975-02-01), Winter et al.
patent: 4617390 (1986-10-01), Hoppe et al.
patent: 4724137 (1988-02-01), Hoppe et al.
patent: 5062882 (1991-11-01), Newton et al.
patent: 5346691 (1994-09-01), Raspani
patent: 5759525 (1998-06-01), Raspani et al.
patent: 5801244 (1998-09-01), Raspani
patent: 5840893 (1998-11-01), Bukrinsky et al.
patent: 6150360 (2000-11-01), Daeyaert et al.
patent: 6288228 (2001-09-01), Henkin et al.
patent: 834507 (1998-04-01), None
patent: 969004 (2000-01-01), None
patent: WO95/30642 (1995-11-01), None
patent: WO98/24782 (1998-06-01), None
patent: WO99/01442 (1999-01-01), None
Graninger et al. Curr. Opin. Rheumatol. 13(3): 209-13, 2001.
Fujiwara et al., Bioorganic & Medicinal Chemistry Letters, vol. 10, p. 1317-1320 (2000).
Raingeaud et al., Molecular And Cellular Biology, vol. 16, No. 3, p. 1247-1255 (Mar. 1996).
Henry et al., Drugs and the Future, vol. 24 (12), p. 1345—1354 (1999).
Bresnihan et al., Arthritis & Rheumantism, vol. 41, No. 12, p. 2196-2204 (Dec. 1998).
Moreland et al., Annals of Internal Medicine, vol. 130, No. 6, p. 478-486 (Mar. 1999).
Bundgaard, Advanced Drug Delivery Reviews, vol. 3, p. 39-65 (1989).
Sabituro et al., Current Medicinal Chemistry, vol. 6, p. 807-823 (1999).
Rankin et al., British Journal of Rheumatology, vol. 34, p. 334-342 (1995).
Kotlyarov et al., Nature Cell Biology, vol. 1, p. 94-97 (1999).
Bodor et al., Annual Reports In Medicinal Chemistry, vol. 22, p. 303-313 (1987).
Ahmed Gulzar
Baldwin John J.
Dyckman Alaric J.
Erickson Shawn David
Henderson Ian
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Pharmaceopeia, Inc.
Wang Joseph C.
Winslow Anastasia P.
LandOfFree
N-heterocyclic inhibitors of TNF-α expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-heterocyclic inhibitors of TNF-α expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-heterocyclic inhibitors of TNF-α expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509215